Keros Therapeutics (KROS) vs Nature's Sunshine Products (NATR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nature's Sunshine Products (NATR) has outperformed Keros Therapeutics (KROS) over the past year, losing 16.2% versus a loss of 27.1%. Over five years, NATR leads with a -18.2% price change compared with -70.1% for KROS. Keros Therapeutics is the larger company by market cap ($230.8 million vs $221.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | NATR |
|---|---|---|
| Share price | $11.64 | $12.57 |
| Market cap | $230.79M | $221.18M |
| 1-day change | +3.84% | -0.16% |
| YTD return | -42.83% | -41.75% |
| 1-year return | -27.07% | -16.20% |
| 5-year return | -70.15% | -18.22% |
| P/E ratio (TTM) | — | 12.45 |
| Forward P/E | — | 10.22 |
| EPS (TTM) | $-3.22 | $1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.55 | $28.14 |
| 52-week low | $9.69 | $12.31 |
| Distance from 52-week high | -48.38% | -55.33% |
| Analyst consensus | buy | none |
| Avg. price target upside | +70.36% | +142.64% |
| Average volume | 194.05K | 160.23K |
| Shares outstanding | 19.83M | 17.60M |
| Employees | 92 | 806 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NATR has outperformed KROS by 10.9 percentage points over the past year.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Nature's Sunshine Products
NATR stock →Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company distributes general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision; and immune products to support and strengthen the human immune system.
Health Care · Biotechnology: Pharmaceutical Preparations · 806 employees
KROS vs NATR FAQ
Which is bigger, Keros Therapeutics or Nature's Sunshine Products?
Keros Therapeutics (KROS) is larger, with a market capitalization of $230.79M compared with $221.18M for Nature's Sunshine Products (NATR).
Which stock has performed better over the past year, KROS or NATR?
NATR returned -16.20% over the past 12 months, compared with -27.07% for KROS (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and Nature's Sunshine Products in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.